Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

D Tc 99m Dimercaptosuccinic Acid SPECT Versus Planar

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04091685
Recruitment Status : Not yet recruiting
First Posted : September 17, 2019
Last Update Posted : September 17, 2019
Sponsor:
Information provided by (Responsible Party):
Marwa Sayed Mohamed, Assiut University

Brief Summary:
Knowing what will DMSA spect add to the DMSA planar in detection in renal cortical defects

Condition or disease Intervention/treatment
Dimercaptosuccinic Acid SPECT and Planar Device: Gamma camera imaging

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Added Value of Tc99m Dimercaptosuccinic Acid SPECT Versus Planar Imaging in Detection of Renal Cortical Defects
Estimated Study Start Date : September 2019
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine



Intervention Details:
  • Device: Gamma camera imaging
    Use gamma camera in detection of renal cortical defects


Primary Outcome Measures :
  1. Comparison between DMSA spect and planar imaging [ Time Frame: Baseline ]
    Analysis of DMSA spect and planar imaging to clarify early renal cortical defects


Secondary Outcome Measures :
  1. Clarify added value of DMSA spect over planar [ Time Frame: Baseline ]
    Know if DMSA spect is necessary?



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Patient with history of peylo nephritis ,malrotated kidney ,ectopic kidney with no age limitation
Criteria

Inclusion Criteria:

  • patient with history of peylo nephritis.

Exclusion Criteria:

  • pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04091685


Contacts
Layout table for location contacts
Contact: Marwa Sayed Mahamed 00201010573518 marwasayed1599@gmail.com
Contact: Mohamed A Mekkawy, PhD 01223196777

Sponsors and Collaborators
Assiut University

Layout table for additonal information
Responsible Party: Marwa Sayed Mohamed, Resident doctor, Assiut University
ClinicalTrials.gov Identifier: NCT04091685     History of Changes
Other Study ID Numbers: DSVP
First Posted: September 17, 2019    Key Record Dates
Last Update Posted: September 17, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Succimer
Technetium Tc 99m Dimercaptosuccinic Acid
Antidotes
Protective Agents
Physiological Effects of Drugs
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Radiopharmaceuticals